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yDITORIAL COMMENT
eft Ventricular Hypertrophy
n Hypertrophic Cardiomyopathy
hat’s in a Phenotype?*
effrey S. Borer, MD, FACC
ew York, New York
eft ventricular myocardial hypertrophy (LVH) occurs in
any conditions, usually, it is thought, as a secondary or
compensatory” response to abnormal pressure or volume
oading and to stimuli, as yet incompletely understood,
esulting from deficiencies in cardiac performance (1).
hese responses may be modulated by genetic predisposi-
ions, a relationship also not well understood. “Compensa-
ory” hypertrophy may prolong the time to symptom devel-
pment in patients with hypertension and valvular heart
iseases and may forestall development of congestive heart
ailure in patients with coronary artery disease. Conversely,
owever, the presence of LVH generally is evidence of an
nderlying problem requiring compensation. Left ventricu-
See page 398
ar myocardial hypertrophy almost invariably involves not
nly the cardiomyocytes that generate contractile force but
lso the cardiac fibroblasts that produce the extracellular
atrix, the scaffold on which the myocytes are organized
nd that transmits contractile force, a key link in the genesis
f cardiac mechanical performance. Alterations in the rela-
ionship of these myocardial components during LVH may
ave an adverse effect on cardiac function. Nutrition and
aintenance of the hypertrophied myocardium impose
urdens that, ultimately, also may add to clinical debility.
ndeed, it is well demonstrated that electrocardiographic or
chocardiographic LVH is directly related to clinical out-
ome among individuals unselected for disease (2,3) and is
particularly potent risk factor for patients with hyperten-
ion, coronary artery disease, or diabetes mellitus (4). Thus,
n a recent comprehensive metanalysis involving almost
0,000 persons, Vakili et al. found that adjusted all-cause
ortality risk averaged 2.3:1 when individuals with LVH at
aseline were compared with those lacking LVH (2),
hereas an assessment of more than 3,000 persons in the
ramingham Heart Study, initially free of clinically appar-
nt cardiovascular disease, indicated an incremental risk of
eveloping disease of approximately 50% for each left
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Pathophysiology and the Howard Gilman
nstitute for Valvular Heart Diseases, Weill Medical College of Cornell University,
dew York, New York.entricular (LV) mass increment of 50 g/m height (3);
gain, all-cause mortality also was associated with LVH.
Though LVH may occur most commonly as a response to
xogenous loads and other diseases (perhaps modulated by
enetic predisposition), hypertrophy may also occur as a
rimary process. Several specific gene mutations now have
een associated with regional or global alterations in myo-
yte size, physical orientation, and contractile protein me-
abolism and function (5). The resulting hypertrophic car-
iomyopathy (HCM) probably is the most common
enetically determined cardiomyopathic condition among
umans, occurring in approximately 0.2% of the general
opulation (6). When the hypertrophy is particularly
arked in the region of the anterior papillary muscle and
uperior septum, abnormal systolic anterior motion of the
nterior mitral valve leaflet can result in LV outflow
bstruction, a dynamic process known as hypertrophic
bstructive cardiomyopathy (HOCM) or idiopathic hyper-
rophic subaortic stenosis. The dynamic obstruction can, in
urn, potentiate hypertrophy by imposing afterload stress on
elatively less affected myocardium, most commonly in the
V free wall. (Indeed, it has been theorized that hypertro-
hy in this disease is entirely secondary, in response to
enetically determined regional dysfunction of a sarcomeric
rotein, perhaps potentiated by abnormal mechanical
tresses imposed on adjacent regions of normal myocardium
6].) In part because of varying degrees of such compensa-
ory hypertrophy together with the variable phenotypic
xpression of the underlying gene mutations, HOCM
ommonly, but not always, is associated with hyperdynamic
V contractile performance and supernormal LV ejection
raction, together with subnormal compliance and diastolic
ysfunction. Non-obstructive HCM also can manifest as
yperdynamic performance, but normal or even subnormal
erformance commonly is apparent. The natural history of
oth forms also is highly variable, though progression to
ontractile deficiency, LV dilation, and a picture reminis-
ent of congestive cardiomyopathy have been described.
The highly variable phenotypic expression of HCM, and
he development over the past decade of evidence of many
ifferent gene mutations that lead to similar phenotypic
anifestations, render overarching generalizations about
he implications of any single phenotypic finding to be
enuous. Nonetheless, one thing, at least, seemed relatively
ertain, specifically, that HCM shared with other diseases
haracterized by hypertrophy the association of particularly
arked LVH (defined for this disease as a maximal left
entricular wall thickness [MLVWT] 30 mm by echocar-
iography) with particularly untoward prognosis (7).
hough reasonable, this view is based in part on inference
nd assumption. The largest and most compelling relevant
tudy involved 480 patients with HCM, 43 of whom had
arked LVH. Age ranged from 1 to 89 years (median, 47
ears). Mortality was 18.2% in the marked LVH cohort
uring an average 6.5-year follow-up and was substantially
l
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July 21, 2004:406–8 Editorial Commentower among those with less LVH. Those with marked
VH were considerably younger (median age, 28 years)
han the remainder of the study cohort. The relatively high
ortality in the group with marked LVH, plus the relative
aucity of marked LVH in the older subgroups, supported
he conclusion that marked LVH is ominous in patients
ith HCM. However, the implicit assumption underlying
nterpretation of these data is that the patients without
arked LVH, a relatively older population, never had
anifested MLVWT30 mm. The study of Thaman et al.
8) in this issue of the Journal refutes this assumption with
erial echocardiographic observations in well-characterized,
arefully studied patients.
Over the course of 15 years, these authors prospectively
dentified 106 patients with HCM and MLVWT 30 mm
nd followed them for an average of almost 8 years. During
his interval, 17% died; 5-year survival from sudden death
as 90.1% and from heart failure death or transplantation,
7.7%. Almost 80% of patients were alive 10 years after
ollow-up began. Because more than 70% of patients were
ounger than age 40 at study initiation, this survival rate is
onsiderably less than might be expected in an unselected
ge-matched ambient population. Nonetheless, this survival
attern suggests that causes other than death at a young age
ust account for the paucity of severe LVH among patients
ith HCM as they age. The authors’ serial echocardio-
raphic substudy, performed in 71 of their 106 patients and
overing a follow-up interval of almost 7 years, provides the
nswer: the LV remodels spontaneously over time, and the
alls thin. Indeed, wall thinning of at least 5 mm occurred
n more than half the patients; this phenomenon also
ccurred predominantly among patients less than 40 years of
ge. Thus, the loss of severe LVH occurred while these
eople still were relatively young. The biology underlying
his change is not known: is it a genetic program that, if
iscovered, could modify prognostic inferences and, more
mportantly, could be applied therapeutically to treat pa-
ients with HCM, as well as patients with other conditions
nvolving pathologic hypertrophy? Is it an adaptive change
esulting secondarily from the effects of abnormal loading,
eurohumoral/hormonal or other exogenous factors caused
y the primary pathophysiology? Answers to these questions
re not known, and should occupy the time of researchers in
he future.
Another noteworthy secondary finding was that marked
VH, by itself, was not the predominant risk factor in this
roup: 5-year freedom from sudden death was 96.5% among
eople who manifested only MLVWT 30 mm, but
rended downward (87.4%) if the marked LVH was asso-
iated with non-sustained ventricular tachycardia, subnor-
al blood pressure response to upright exercise testing,
amily history of sudden cardiac death, or unexplained
yncope, factors previously identified as prognostically im-
ortant for patients with HCM. Thus, the present study
oes not negate concern about young patients with HCM
ho manifest marked LVH, but suggests that strategies toaximize their survival must be modified with reference to
ssociated risk factors and to the variable natural history of
he condition, which can include spontaneous wall thinning.
To be sure, the present study must be understood in the
ontext of its limitations, most of them very difficult to
void. First are the twin problems of referral bias and
election bias. The study site is a specialized center for
CM management and research within a major tertiary
eferral hospital. The majority of patients were referred from
lsewhere for opinions about management or risk stratifi-
ation, suggesting a potential bias toward relatively severely
fflicted individuals. Other patients were seen as part of
amily surveys and, presumably, were asymptomatic and
iscovered serendipitously. Such a convenience sample may
ot faithfully represent the full range and course of HCM
ith severe LVH. However, the study cohort is sufficiently
arge and sufficiently diverse so that the primary finding,
hat wall thinning occurs spontaneously, not only can be
ccepted but plausibly can be considered relevant to a
ubstantial portion of the HCM/severe LVH subpopula-
ion. Another potentially important limitation is the inabil-
ty of the study design to account for the possible interaction
f drugs and/or devices with the disease in affecting
LVWT or outcome. Although it is unlikely that treat-
ent could have affected the primary conclusion, other
nteresting aspects of the findings may well have been
onfounded quantitatively if not qualitatively by uncon-
rolled use of drugs and devices.
Limitations notwithstanding, this is an important study.
he overarching conclusion is that it is necessary to associ-
te phenotypic expressions of disease, such as LVH, with
he underlying biology to define prognosis and to plan
anagement optimally. In an era characterized by an
xplosion of knowledge at the molecular level, this message
s being heard ever more frequently and more clearly in
ardiology. The findings of Thaman et al. (8) strongly
uggest that an intrinsic genetic program is activated by as
et unknown factors to modify hypertrophy in patients with
CM. Understanding and harnessing this program may
rovide substantial benefit in areas unrelated to HCM.
inally, these data indicate that risk stratification in patients
ith HCM, and preventive strategies that may be under-
aken on the basis of hypotheses or incomplete knowledge,
ow must be modified to account for the relative prognostic
mportance of risk factors other than marked LVH alone.
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